Related references
Note: Only part of the references are listed.Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation
Sachin H. Bhagchandani et al.
SCIENCE ADVANCES (2023)
A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives
Peng Liu et al.
MOLECULES (2022)
Polarization of tumor-associated macrophages by TLR7/8 conjugated radiosensitive peptide hydrogel for overcoming tumor radioresistance
Yumin Zhang et al.
BIOACTIVE MATERIALS (2022)
Systemic vaccination induces CD8+T cells and remodels the tumor microenvironment
Faezzah Baharom et al.
CELL (2022)
The expanding role for small molecules in immuno-oncology
Rienk Offringa et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Engineering precision nanoparticles for drug delivery
Michael J. Mitchell et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma
Giulia Agliardi et al.
NATURE COMMUNICATIONS (2021)
Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy
Xiaoqi Sun et al.
NATURE NANOTECHNOLOGY (2021)
Systemic Immunotherapy with Micellar Resiquimod-Polymer Conjugates Triggers a Robust Antitumor Response in a Breast Cancer Model
Hamilton Kakwere et al.
ADVANCED HEALTHCARE MATERIALS (2021)
Dual-target IL-12-containing nanoparticles enhance T cell functions for cancer immunotherapy
Jieyu Li et al.
CELLULAR IMMUNOLOGY (2020)
Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours
Aslan Mansurov et al.
NATURE BIOMEDICAL ENGINEERING (2020)
The Efficacy of Cholesterol-Based Carriers in Drug Delivery
Ngonidzashe Ruwizhi et al.
MOLECULES (2020)
Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity
Yingzhong Li et al.
NATURE CANCER (2020)
Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator
Ruolin Lu et al.
JOURNAL OF CONTROLLED RELEASE (2019)
A Designer Scaffold with Immune Nanoconverters for Reverting Immunosuppression and Enhancing Immune Checkpoint Blockade Therapy
Hathaichanok Phuengkham et al.
ADVANCED MATERIALS (2019)
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
Stefanie R. Mullins et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy
Sun-Young Kim et al.
ACS NANO (2019)
Latest Advances in Small Molecule TLR 7/8 Agonist Drug Research
David C. McGowan
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
Small Molecules Drive Big Improvements in Immuno-Oncology Therapies
Bayard R. Huck et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
Revisiting Interleukin-12 as a Cancer Immunotherapy Agent
Pedro Berraondo et al.
CLINICAL CANCER RESEARCH (2018)
Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes
Feng-Ying Huang et al.
ONCOIMMUNOLOGY (2018)
TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
Christopher B. Rodell et al.
NATURE BIOMEDICAL ENGINEERING (2018)
Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses
Lutz Nuhn et al.
ADVANCED MATERIALS (2018)
Lipid-Drug Conjugate for Enhancing Drug Delivery
Danielle Irby et al.
MOLECULAR PHARMACEUTICS (2017)
An Enzyme-Directed Imidazoquinoline for Cancer Immunotherapy
Joseph D. Hantho et al.
CHEMMEDCHEM (2016)
Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators
Hilmar Weinmann
CHEMMEDCHEM (2016)
TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function
Thibaud Spinetti et al.
ONCOIMMUNOLOGY (2016)
Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses
Christian Hotz et al.
ONCOIMMUNOLOGY (2016)
Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells
Jing Wang et al.
JOURNAL OF IMMUNOLOGY (2015)
Organic Carbamates in Drug Design and Medicinal Chemistry
Arun K. Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity
Geoffrey M. Lynn et al.
NATURE BIOTECHNOLOGY (2015)
Amino Acid Carbamates As Prodrugs Of Resveratrol
Andrea Mattarei et al.
SCIENTIFIC REPORTS (2015)
New insights into IL-12-mediated tumor suppression
S. Tugues et al.
CELL DEATH AND DIFFERENTIATION (2015)
Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment
Awwad A. Radwan et al.
MOLECULES (2014)
Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release
Petr O. Ilyinskii et al.
VACCINE (2014)
Targeting cancer using cholesterol conjugates
Awwad A. Radwan et al.
SAUDI PHARMACEUTICAL JOURNAL (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Carbamate Stabilities of Sterically Hindered Amines from Quantum Chemical Methods: Relevance for CO2 Capture
Satesh Gangarapu et al.
CHEMPHYSCHEM (2013)
Structure activity relationships in Toll-like receptor 7 agonistic 1H-imidazo[4,5-c]pyridines
Euna Yoo et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2013)
Polarization and reprogramming of myeloid-derived suppressor cells
Wen-Chin Yang et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2013)
Immunogenic cell death and DAMPs in cancer therapy
Dmitri V. Krysko et al.
NATURE REVIEWS CANCER (2012)
Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance
Carole Bourquin et al.
CANCER RESEARCH (2011)
Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction
Dmitri Smirnov et al.
VACCINE (2011)
Injectable Lipid Emulsions-Advancements, Opportunities and Challenges
Ketan Hippalgaonkar et al.
AAPS PHARMSCITECH (2010)
Structure-Property Relationships of a Class of Carbamate-Based Fatty Acid Amide Hydrolase (FAAH) Inhibitors: Chemical and Biological Stability
Federica Vacondio et al.
CHEMMEDCHEM (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration
A. C. Inge Boullart et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics
Naoki Umemura et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy
Evelien L. J. M. Smits et al.
ONCOLOGIST (2008)
Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents
Yonghong Shi et al.
CANCER RESEARCH (2007)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-γ production
OM Hart et al.
JOURNAL OF IMMUNOLOGY (2005)
Interleukin-12 and the regulation of innate resistance and adaptive immunity
G Trinchieri
NATURE REVIEWS IMMUNOLOGY (2003)
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848
M Jurk et al.
NATURE IMMUNOLOGY (2002)
Share Paper
